• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Skip to investors navigation
Insmed

Insmed

Powered by Purpose

LinkedIn Twitter Contact Us Job Opportunities

  • Culture
    • Our Culture
      • Mission & Vision
      • Careers
      • Responsibility
        • Inclusion at Insmed
        • Grants & Funding
        • Global Healthcare Compliance

    Our Global Company

    Find available career opportunities in the U.S., Japan, or Europe.

    Find Jobs

  • Patients
    • Our Patients
      • Disease Areas
        • NTM Lung Disease
        • Bronchiectasis
        • Pulmonary Arterial Hypertension
      • Resources
      • Patient Access

    Current Clinical Trials

    You may be eligible for one of our clinical trials.

    See if you may qualify

  • Science
    • Our Science
      • ARIKAYCE®
      • Our Programs
      • Pipeline
      • Clinical Trials
      • Our Research Team
      • Investigator-Initiated Research

    Our Research Team

    Working together to develop new medicines and technologies that have the potential to transform patients’ lives.

    Learn More

  • About
    • About Insmed
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs
Home / Investors/ News Releases

News Releases

Month Year
Su Mo Tu We Th Fr Sa
Month Year
Su Mo Tu We Th Fr Sa
Email Alerts
Advanced Search
  
Asset Types
           
 Basic Search
  • May 12, 2006
    Insmed Incorporated to Present at the Rodman & Renshaw 3rd Annual Healthcare Conference
  • May 8, 2006
    Insmed Incorporated Reports Financial Results for the First Quarter Ended March 31, 2006
  • May 2, 2006
    Insmed Inc. to Webcast 2006 First Quarter Financial Results Conference Call, Monday May 8, 2006 at 4:30 p.m. (ET)
  • May 1, 2006
    IPLEX(TM) Demonstrates Significant, Dose-Dependent Increases in Growth Rate
  • Apr 26, 2006
    Insmed Announces Podium Presentation at the Pediatric Academic Societies' 2006 Annual Meeting
  • Apr 25, 2006
    NORD Honors Insmed for Role in Developing Treatments for Rare Diseases
  • Mar 22, 2006
    Insmed Announces Additional Information in Compliance with NASDAQ Rules
  • Mar 15, 2006
    Insmed Completes $46 Million Public Offering; Underwriters Exercise In Full Option to Purchase Additional Shares
  • Mar 10, 2006
    Insmed Prices $40 Million Equity Offering
  • Mar 6, 2006
    Insmed Incorporated Announces Proposed Public Offering of Common Stock
  • Mar 2, 2006
    Insmed Incorporated Reports Financial Results for the Fourth Quarter and Twelve-Months of 2005
  • Feb 23, 2006
    Insmed to Announce 2005 Fourth Quarter and Year End Financial Results; Thursday, March 2
  • Feb 3, 2006
    Insmed Incorporated Files Shelf Registration Statement
  • Jan 4, 2006
    U. of Rochester Initiates Phase 2 Clinical Trial of Insmed's iPlex for the Treatment of Myotonic Muscular Dystrophy; Trial Funded by NIH and MDA Grants
  • Dec 12, 2005
    FDA Approves Insmed's Orphan Drug, IPLEX, for the Treatment of Severe Primary IGF-1 Deficiency; The First Once-Daily Therapy for the Treatment of Severe Primary IFG-1 Deficiency
  • Dec 8, 2005
    Insmed Responds to Complaint Filed by Tercica
  • Nov 28, 2005
    Insmed to Present at the Lazard Capital Markets Life Sciences Conference
  • Nov 5, 2005
    Insmed Incorporated Reports Financial Results for the Third Quarter and First Nine Months of 2005
  • Nov 2, 2005
    Insmed to Present at the Rodman and Renshaw 7th Annual Healthcare Conference
  • Nov 1, 2005
    Insmed to Release Third Quarter Financial Results; Thursday, November 3
  • Oct 25, 2005
    Insmed Receives European Orphan Drug Designation for SomatoKine for the Treatment of Extreme Insulin Resistance; Company to Initiate Clinial Trial in Type A Insulin Resistance
  • Oct 25, 2005
    FDA to Review Insmed's Complete Response to Approvable Letter for iPlex
  • Oct 24, 2005
    Insmed to Present at the C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference
  • Oct 18, 2005
    Insmed to Present at the BIO Investor Forum Conference
  • Oct 17, 2005
    Insmed Submits Response to FDA Approvable Letter for iPlex
Show 5102550100 per page
  • «
  • 1
  • …
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • »
Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download

Primary Sidebar

Investor Menu

  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

Investor Menu

Footer

Insmed
LinkedIn Twitter

Contact Us

Job Opportunities

  • Our Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Our Patients
    • Disease Areas
      • NTM Lung Disease
      • Bronchiectasis
      • Pulmonary Arterial Hypertension
    • Resources
    • Patient Access
  • Our Science
    • ARIKAYCE®
    • Our Programs
    • Pipeline
    • Clinical Trials
    • Our Research Team
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

© 2022 Insmed Incorporated. All Rights Reserved. Terms of Use Privacy Policy

Culture
Patients
Science
logo
  • Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Patients
    • Disease Areas
      • NTM Lung Disease
      • Bronchiectasis
      • Pulmonary Arterial Hypertension
    • Resources
    • Patient Access
  • Science
    • ARIKAYCE®
    • Our Programs
    • Pipeline
    • Clinical Trials
    • Our Research Team
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs

LinkedIn Twitter

Contact Us Job Opportunities

© 2022 Insmed Incorporated.
All Rights Reserved.

Terms of Use Privacy Policy